Loading
Giving slightly more thyroid hormone than the body needs after thyroid cancer surgery, to switch off the pituitary signal that could feed leftover cancer cells.
TSH suppression is the practice of giving slightly more levothyroxine than the body needs after thyroid cancer surgery, so that TSH stays below the normal range and the pituitary signal that could feed leftover cancer cells is switched off. The degree of suppression is tailored to recurrence risk, with low-risk differentiated thyroid cancer needing the least. Long-term over-suppression causes bone loss and atrial fibrillation, so guidelines now recommend a normal-range TSH for low-risk patients after a few years. Readers meet the term on the thyroid cancer page, and it is linked from the survivorship bottleneck because it is a long-term treatment whose late effects are easily neglected.
Site decides cause and behaviour: HPV drives oropharyngeal cancer, EBV drives nasopharyngeal cancer, tobacco drives oral and laryngeal cancer; all drain into the neck node levels that surgeons and radiotherapists map.
Same organ: Acinic cell carcinoma of the salivary glands, Carcinoma ex pleomorphic adenoma, Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2A and MEN2B), Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma), Oropharyngeal cancer (tonsil and base of tongue), Laryngeal and hypopharyngeal cancer, Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma, Nasopharyngeal carcinoma, Salivary gland cancers, Papillary thyroid cancer, Follicular thyroid cancer, Medullary thyroid cancer, Anaplastic thyroid cancer, Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma), NUT carcinoma (midline carcinoma with NUTM1 rearrangement), Parathyroid carcinoma, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), HPV-positive oropharyngeal cancer, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Recurrent or metastatic head and neck squamous cell carcinoma, Hypopharyngeal cancer, Adenoid cystic carcinoma, Salivary duct carcinoma, Mucoepidermoid carcinoma, Oral tongue and floor of mouth cancer, Buccal mucosa and gingivobuccal cancer (oral cancer in India), Lip cancer, Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Recurrent and metastatic nasopharyngeal carcinoma, Esthesioneuroblastoma (olfactory neuroblastoma), Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma
Showing the organ this term concerns: Thyroid cancer.
Shares Low-risk differentiated thyroid cancer (ATA risk), Thyroid cancer.
Shares Low-risk differentiated thyroid cancer (ATA risk), Thyroid cancer.
Shares Low-risk differentiated thyroid cancer (ATA risk), Thyroid cancer.
Shares Low-risk differentiated thyroid cancer (ATA risk), Thyroid cancer.
Shares Thyroid cancer, Survivorship and late effects are neglected.
Shares Low-risk differentiated thyroid cancer (ATA risk), Thyroid cancer.
Shares Thyroid cancer, Survivorship and late effects are neglected.
Shares Thyroid cancer, Survivorship and late effects are neglected.